Pomotrelvir for COVID-19: real-time analysis

Download Image

Post

c19early.org

Pomotrelvir for COVID-19

1 study with 230 patients

No significant improvements are seen in meta-analysis to date.

COVID-19 Pomotrelvir studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−1%

Viral clearance (1)−39%

RCTs (1)−1%

Early (1)−1%

00.511.5+

← Pomotrelvir
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Feb 6 2024	Borroto-Esoda et al., Microbiology Spectrum, doi:10.1128/spectrum.02980-23	SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir
Feb 6 2024	1% worse recovery (p=1) and 252% worse results (p=0.1). RCT 242 symptomatic outpatients showing no significant difference in viral clearance or symptom resolution with pomotrelvir treatment initiated within 5 days of symptom onset. Based on the description provided it is not clear why the numb..